![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine,1 Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan 48109-06422
Received 29 June 2001/ Returned for modification 9 August 2001/ Accepted 27 September 2001
 |
ABSTRACT |
|---|
 Top Abstract TextReferences |
|---|
|
TEXT |
|---|
|
TopAbstractTextReferences |
|---|
-linolenic, arachidonic, or eicosanopentaenoic acid and include the prostaglandins and leukotrienes. Prostaglandins (e.g., prostaglandin D2 [PGD2], PGE2, and PGF2
) are produced via the initial action of prostaglandin G/H synthase (cyclooxygenase) followed by specific prostaglandin synthases. Leukotrienes are produced via a lipoxygenase (LOX) followed by conversion into leukotriene B4 (LTB4) and the cysteinyl leukotrienes (LTC4, LTD4, and LTE4) by different synthases and hydrolases. Prostaglandins can inhibit Th1 type immune responses, chemokine production, phagocytosis, and lymphocyte proliferation (3, 9, 11, 14, 17, 19, 20). Leukotrienes are potent leukocyte chemotactic factors (7). Prostaglandins and leukotrienes can also promote Th2 type responses and tissue eosinophilia (4, 7, 11, 14, 18). In the context of antifungal immunity, chronic or disseminating fungal infections will result if the early Th1/Th2 balance of cellular immunity is shifted away from Th1 toward Th2 type responses (16). Thus, enhanced prostaglandin production during fungal infection could be an important factor in promoting fungal colonization and chronic infection. Host cells are one source of eicosanoids during fungal infection; however, another potential source of eicosanoids is the fungal pathogen itself. We recently reported that the pathogenic yeasts Cryptococcus neoformans and Candida albicans produce prostaglandins de novo and when fed exogenous arachidonic acid (AA) (13). In addition, yeast-derived PGE could inhibit lymphocyte proliferation, decrease tumor necrosis factor alpha production, and augment interleukin-10 production (13). Our objective was to determine if eicosanoid production extended to other pathogenic fungi, including dermatophytes (Epidermophyton floccosum, Fusarium dimerum, Microsporum audouinii, Microsporum canis, and Trichophyton rubrum), subcutaneous pathogens (Sporothrix schenckii), and systemic pathogens (Absidia corymbifera, Aspergillus fumigatus, Histoplasma capsulatum, Blastomyces dermatitidis, Penicillium spp., Rhizopus spp., and Rhizomucor pusillus).
To examine eicosanoid production in various species of pathogenic fungi, PGE2, PGD2, PGF2, LTB4, and cysteinyl leukotriene (CysLT) levels from culture supernatants were measured. H. capsulatum and B. dermatitidis were grown for 7 days at 37°C in RPMI medium while shaking. All others were grown for 7 days at 25°C in RPMI medium while shaking. The cultures were incubated for an additional 2 h with 1 mM AA (Cayman Chemicals, Ann Arbor, Mich.). Culture supernatants from both AA-fed and non-AA-fed fungi were analyzed for eicosanoid production using enzyme-linked immunosorbent assay kits (Cayman Chemicals) for PGE2, PGD2, PGF2, LTB4, and CysLT (detects LTC4, LTD4, and LTE4) according to the manufacturer’s instructions. The cultures without AA measure the (endogenous) production of eicosanoids by fungi in the absence of exogenous fatty acid substrates (RPMI medium is a defined medium devoid of fatty acids). All fungal strains grown in RPMI medium alone produced PGE2, PGD2, PGF2, LTB4, and CysLT (Table 1). In the presence of exogenous AA, approximately 10-fold more of each eicosanoid was detected in the cultures (Table 2). C. neoformans and C. albicans also produced both prostaglandins and leukotrienes from exogenous AA. These data demonstrate that all of these pathogenic fungi have the ability to convert exogenous AA into both LOX- and prostaglandin G/H synthase-derived eicosanoids. Thus, pathogenic fungi have the ability to produce eicosanoids both from simple metabolites and from exogenous AA.
|
|
Why do fungi produce eicosanoids? Since the fungi reported in this work represent a diverse group of organisms, one possibility is that there is a link between eicosanoid production and fungal growth. We previously reported that indomethacin and etodolac (prostaglandin G/H synthase inhibitors) could inhibit the growth of C. neoformans and C. albicans (13). We have also observed that nordihydroguaiaretic acid (a LOX inhibitor) can also inhibit the growth of these fungi (data not shown).
The precise role of fungal eicosanoids in the pathogenesis of fungal diseases remains to be determined, but the potential link between fungal eicosanoids and the development of atopic diseases in the host is intriguing. The role of eicosanoids in the pathogenesis of allergy and asthma is well documented (2–4, 7, 8, 11, 13, 14, 16, 21). Fungi elicit a variety of allergic diseases, including asthma, sinusitis, allergic bronchopulmonary mycoses, and hypersensitivity pneumonitis (6, 10, 15). As demonstrated in this study, fungi produce immunologically active mediators that can promote the development and manifestation of atopic responses to the infection itself or fungal antigens. By analogy, schistosome-derived PGD2 was recently reported to play a role in the immune deviation that occurs following skin infection by this parasite (1). Thus, the discovery that pathogenic fungi produce eicosanoids opens up a new realm of investigation for virulence mechanisms in fungal pathogenesis and also for fungal eicosanoids as potential cofactors of atopic diseases.
|
ACKNOWLEDGMENTS |
|---|
This work was supported by a New Investigator Award in Molecular Pathogenic Mycology from the Burroughs-Wellcome Fund (G.B.H.). M.C.N. is also supported by NIH-NIAID training grant T32AI07528.
|
FOOTNOTES |
|---|
|
REFERENCES |
|---|
|
TopAbstractTextReferences |
|---|
| 1. | Angeli, V., C. Faveeuw, O. Roye, I. Fontaine, M. Capron, and F. Trottein. 2001. Role of the parasite-derived prostaglandin D2 in the inhibition of epidermal langerhans cell migration during schistosomiasis infection. J. Exp. Med. 193: 1135–1147. |
| 2. | Barnes, P., M. Belvisi, R. Newton, and J. Mitchell. 1998. Cyclooxygenase-2 expression in airway cells, p. 111–127. In C. Lenfant (ed.), Eicosanoids, aspirin, and asthma, vol. 114. Marcel Dekker, Inc., New York, N.Y. |
| 3. | Betz, M., and B. S. Fox. 1991. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J. Immunol. 146: 108–113.[Abstract] |
| 4. | Demeure, C. E., L.-P. Yang, C. Desjardins, P. Raynauld, and G. Delespesse. 1997. Prostaglandin E2 primes naive T cells for the production of anti-inflammatory cytokines. Eur. J. Immunol. 27: 3526–3531.[Medline] |
| 5. | Ghannoum, M. 2000. Potential role of phospholipases in virulence and fungal pathogenesis. Clin. Microbiol. Rev. 13: 122–143. |
| 6. | Horner, W. E., A. Helbling, J. E. Salvaggio, and S. B. Lehrer. 1995. Fungal allergens. Clin. Microbiol. Rev. 8: 161–179.[Abstract] |
| 7. | Jonsson, E., and S. Dahlen. 1999. The role of eicosanoids in inflammation and allergy, p. 233–272. In F. Marks and G. Furstenberger (ed.), Prostaglandins, leukotrienes, and other eicosanoids. Wiley-VCH, Weinheim, Germany. |
| 8. | Kaufman, H., J. Tomee, T. van der Werf, J. de Monchy, and G. Koeter. 1995. Review of fungus-induced asthmatic reactions. Am. J. Respir. Care Med. 151: 2109–2116.[Abstract] |
| 9. | Kunkel, S. L., M. Spengler, M. A. May, R. Spengler, J. Larrick, and D. Remick. 1988. Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression. J. Biol. Chem. 263: 5380–5384. |
| 10. | Kurup, V., H. Shen, and B. Banerjee. 2000. Respiratory fungal allergy. Microbes Infect. 2: 1101–1110.[CrossRef][Medline] |
| 11. | Matsuoka, T., M. Hirata, H. Tanaka, Y. Takahashi, T. Murata, K. Kabashima, Y. Sugimoto, T. Kobayashi, F. Ushikubi, Y. Aze, N. Eguchi, Y. Urade, N. Yoshida, K. Kimura, A. Mizoguchi, Y. Honda, H. Nagai, and S. Narumiya. 2000. Prostaglandin D2 as a mediator of allergic asthma. Science 287: 2013–2019. |
| 12. | Nicosia, S., V. Capra, and G. Rovati. 2001. Leukotrienes as mediators of asthma. Pulm. Pharmacol. Ther. 14: 3–19.[CrossRef][Medline] |
| 13. | Noverr, M., S. Phare, G. Toews, M. Coffey, and G. Huffnagle. 2001. Pathogenic yeasts Cryptococcus neoformans and Candida albicans produce immunomodulatory prostaglandins. Infect. Immun. 69: 2957–2963. |
| 14. | Peters-Golden, M. 1997. Lipid mediator synthesis by lung macrophages, p. 151–182. In M. F. Lipscomb and S. W. Russell (ed.), Lung macrophages and dendritic cells in health and disease, vol. 102. Marcel Dekker, Inc., New York, N.Y. |
| 15. | Ponikau, J., D. Sherris, E. Kern, H. Homberger, E. Frigas, T. Gaffey, and G. Roberts. 1999. The diagnosis and incidence of allergic fungal sinusitis. Mayo Clin. Proc. 74: 877–884.[Medline] |
| 16. | Romani, L., and S. H. Kaufmann (ed.). 1998. Immunity to fungi. Research in immunology, vol. 149. Elsevier, Amsterdam, The Netherlands. |
| 17. | Sergeeva, M. G., M. V. Gonchar, A. T. Mevkh, and S. D. Varfolomeyev. 1997. Prostaglandin E2 biphasic control of lymphocyte proliferation inhibition by picomolar concentrations. FEBS Lett. 418: 235–238.[CrossRef][Medline] |
| 18. | Snijdewint, F. G., P. Kalinski, E. A. Wierenga, J. D. Bos, and M. L. Kapsenberg. 1993. Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J. Immunol. 150: 5321–5329.[Abstract] |
| 19. | Standiford, T. J., S. L. Kunkel, M. W. Rolfe, H. L. Evanoff, R. M. Allen, and R. M. Strieter. 1992. Regulation of human alveolar macrophage- and blood monocyte-derived interleukin-8 by prostaglandin E2 and dexamethasone. Am. J. Respir. Cell Mol. Biol. 6: 75–81. |
| 20. | Strassmann, G., V. Patil-Koota, F. Finkelman, M. Fong, and T. Kambayashi. 1994. Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2. J. Exp Med. 180: 2365–2370. |
| 21. | Yamaoka, K., J. Kolb, N. Miyasaka, G. Inuo, and K. Fujita. 1993. Leukotriene B4 induces interleukin 5 generation from human T lymphocytes. Eur. J. Immunol. 23: 2392–2398.[Medline] |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|
